AxoGen (AXGN) CEO On Positive Phase 3 Results

AxoGen (AXGN) announced positive topline results from a phase 3 study for the Avance Nerve Graft. President, CEO, and Chairman Karen Zaderej weighs in on the tissue product moving into the biological category. Avance Nerve Graft would be used whenever a nerve is cut anywhere on the body and in the peripheral nervous system. This would repair the nerve. Nerve damage can occur from kitchen knives to vehicle accidents to power tools.

The Watch List

21 Nov 2022

ON AIR
10:00 am
Trading 360
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
3:30 am
Trading 360
REPLAY
4:30 am
Next Gen Investing
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
Fast Market
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
ON AIR
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
education
3:30 pm
Your First Trade
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
education
7:00 pm
Your First Trade
REPLAY
7:30 pm
Trading 360
REPLAY
8:30 pm
Fast Market
REPLAY
9:30 pm
Next Gen Investing
REPLAY
education
10:30 pm
Your First Trade
REPLAY
11:00 pm
Trading 360
REPLAY

Get the Market Minute

Daily insights for every investor

coming soon

We are now

coming soon

We are now